I-Corps: Lymphedema Intervention Exercise for Breast Cancer Survivors

I-Corps：乳腺癌幸存者的淋巴水肿干预运动

• 批准号: 1740385
• 负责人: Yao Wang
• 金额: $ 5万
• 依托单位: New York University
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-03-15 至 2018-08-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1740385&HistoricalAwards=false
• 关键词: Corps; Lymphedema; Intervention; Exercise; Breast

The broader impact/commercial potential of this I-Corps project is its benefit for millions of individuals who are at risk for or have developed chronic lymphedema, including patients who have been treated for breast cancer and other cancers (head and neck, prostate, melanoma, gynaecological cancer). Lymphedema is a progressive and chronic swelling with many distressful symptoms after cancer treatment. Each year, 1.38 million women worldwide and more than 230,000 women in the US are diagnosed with breast cancer. At least 20-40% of breast cancer survivors have developed lymphedema and the rest of them are at lifelong risk for lymphedema. This project further develops a lymphatic therapy effective in reducing the risk of lymphedema and relieving lymphedema symptoms for breast cancer survivors. The approach may potentially be applied more broadly to individuals with chronic heart failure, end-stage renal disease and hypertension with similar abnormal fluid accumulation symptoms.This I-Corps project explores the commercial potential of a lymphatic therapy. The core technology consists of a physical therapy system that can automatically and accurately track a patient's movement and evaluate it against the desired movement. The system provides instant feedback on whether a patient is performing an exercise correctly and how should the patient make adjustments in their movement. Furthermore, the system will be designed to motivate the patient to perform the therapy correctly and regularly. The system will leverage the novel computer vision and machine learning algorithms being developed in an on-going research project in order to overcome the sensor constraints in detecting joint positions and the significant variability of the normal range of the desired movement, which are the major technical obstacles faced by current sensor-based physical therapy systems.

该 I-Corps 项目更广泛的影响/商业潜力在于，它可以造福数百万有慢性淋巴水肿风险或已患慢性淋巴水肿的人，包括接受乳腺癌和其他癌症（头颈癌、前列腺癌、黑色素瘤、妇科癌症）治疗的患者。淋巴水肿是一种进行性慢性肿胀，在癌症治疗后会出现许多令人痛苦的症状。每年，全球有 138 万名女性和美国超过 23 万名女性被诊断患有乳腺癌。至少 20-40% 的乳腺癌幸存者出现淋巴水肿，其余人终生面临淋巴水肿风险。该项目进一步开发了一种淋巴疗法，可有效降低乳腺癌幸存者的淋巴水肿风险并缓解淋巴水肿症状。该方法可能会更广泛地应用于患有慢性心力衰竭、终末期肾病和高血压且具有类似异常积液症状的个体。该 I-Corps 项目探讨了淋巴疗法的商业潜力。 核心技术包括物理治疗系统，该系统可以自动准确地跟踪患者的运动并根据所需的运动对其进行评估。该系统提供关于患者是否正确进行锻炼以及患者应如何调整动作的即时反馈。 此外，该系统的设计目的是激励患者正确、定期地进行治疗。该系统将利用正在进行的研究项目中开发的新型计算机视觉和机器学习算法，以克服传感器在检测关节位置方面的限制以及所需运动正常范围的显着变化，这是当前基于传感器的物理治疗系统面临的主要技术障碍。